Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may predict COVID-19 danger in transplant patients

NCT ID NCT04369456

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a blood sample can predict how severe COVID-19 will become in kidney transplant patients with mild to moderate symptoms. Researchers measured a protein called IL-6 after stimulating the blood sample. They followed 52 patients to see if IL-6 levels were linked to worsening illness, such as needing intensive care. The goal is to find early warning signs to improve patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which kidney transplant patients with COVID-19 are at higher risk of severe illness, allowing earlier intervention.
What could go wrong
This is a small, observational study (52 participants) that only looks at biomarkers, not a treatment. The findings may not apply to all patients or lead to direct clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

Sep 2020

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Kidney or kidney-pancreas or kidney-heart transplant patients; * SARS-CoV-2 positive (RT-PCR); * COVID-19 symptoms at least once over a 8-day period preceding inclusion; * Hospitalized or outpatients in one of the study centers: CHU de Nice, CHU de Strasbourg, Hôpital Necker (APHP), Hôpital Kremlin Bicêtre (APHP), Hôpital Pitié-Salpétriêre (APHP), Hospices Civils de Lyon, CHU de Saint-Etienne, CHU de Montpellier, Hôpital La Conception (APHM); * Age \> 18 years; * Free and informed consent. Exclusion Criteria: * Age \> 85 years ; * Kidney-liver transplant patients; * Onset of symptoms (fever and/or cough) for more than 8 days; * Acute respiraytory distress despite oxygen therapy, 02 ≥ 4L/min, arterial pressure \< 85/55 mmHg or hemodynamic instability at time of inclusion, encephalopathy with Glasgow coma scale \< 14; * Treatment with non-steroids anti-inflammatory agents within the last 14 days preceding onset of symptoms; * Active bacterial or fungal infection documented at inclusion; * Pregnancy; * Under guardianship or curatorship; * Non-affiliated person with Social Security

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronavirus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronavirus infection Kidney transplant; complications

Contacts and locations

Locations

  • APHM

    Marseille, 13000, France

  • APHP

    Paris, 75000, France

  • Lyon Univerity Hospital

    Lyon, 69000, France

  • Montpellier University Hospital

    Montpellier, 34000, France

  • Saint Etienne University Hospital

    Saint-Etienne, 42000, France

  • Strasbourg Univeristy Hospital

    Strasbourg, 67000, France

  • University Nice Hospital

    Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.